In the article
Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer
Bergen E, Berghoff A.S, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader R.M, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger G.G, Bartsch R.
Breast Care 2014; 9: 344-348 (DOI:10.1159/000368330)
Figures 1 and 2 were identical.
Fig. 2.
Kaplan-Meier estimates for overall survival (OS). Median OS in patients receiving taxanes plus trastuzumab (group A) was 49 months (95% CI, 38.24-59.76) and 59 months (95% CI, 41.17-76.83) in patients receiving oral vinorelbine plus trastuzumab (log-rank test; p = 0.033).
The correct fig. 2 is the following: